Similarly, SPNS2 has been shown to deliver S1P to S1PR2, leading to increased epidermal growth factor (EGF)-mediated cancer cell invasion [119], suggesting that SPNS2 inhibitors may be useful therapeutics for cancer treatment. This evidence concerns the gene EGF and cancer.